Use of dihydroimidazolones for the treatment of dogs

Abstract

The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

1 . Use of 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one or a physiologically acceptable salt thereof as an active ingredient for the manufacture of a medicament for the treatment of epilepsy in dogs.  
     
     
         2 . The use of  claim 1  wherein the medicament is for oral administration.  
     
     
         3 . The use of  claim 1  wherein the medicament is administered 1-5 times daily.  
     
     
         4 . The use of  claim 1  wherein the daily dose of the active ingredient is from 1 to 200 mg/kg.  
     
     
         5 . The use of any one of claims  1 - 4  wherein the active ingredient is co-administered with at least one further active ingredient.  
     
     
         6 . The use of  claim 5  wherein the further active ingredient is selected from phenobarbital, primidone and potassium bomide.  
     
     
         7 . The use of any one of claims  1 - 6  wherein the epilepsy is idiopathic or symptomatic epilepsy.  
     
     
         8 . The use of any one of claims  1 - 7  for the treatment of newly diagnosed epilepsy.  
     
     
         9 . The use of any of claims  1 - 7  for the treatment of drug-resistant epilepsy.  
     
     
         10 . Use of 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one or a physiologically acceptable salt thereof as an active ingredient for the manufacture of a medicament for the treatment of behavioural abnormalities in dogs.  
     
     
         11 . The use of  claim 10  for the treatment of anxiety.